Organofluorides

First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

Retrieved on: 
Monday, April 6, 2020
Medicine, Health, Clinical medicine, Clinical research, Deception, Placebo, Organofluorides, Monoclonal antibodies, Durvalumab, Upadacitinib

This trial is a Phase 2b/3 for severely ill COVID-19 patients and is for 342 patients, double-blinded with a 2:1 ratio (drug to placebo ratio).

Key Points: 
  • This trial is a Phase 2b/3 for severely ill COVID-19 patients and is for 342 patients, double-blinded with a 2:1 ratio (drug to placebo ratio).
  • Patients enrolled in this trial are expected to be administered leronlimab for two weeks, with the primary endpoint being the mortality rate at 14 days.
  • The Company will perform an interim analysis on the data from 50 patients following two weeks of leronlimab therapy.
  • Our team is working hard to distribute leronlimab to multiple clinical sites to initiate therapy in patients with severe COVID-19 disease.

U.S. Environmental PFAS Treatment Market 2020-2024 - Demand Soaring for Sample Testing and Site Assessment to Quantify the Challenge

Retrieved on: 
Friday, April 3, 2020
Fluorosurfactant, Organofluorides, Pollutants, Surfactants

DUBLIN, April 3, 2020 /PRNewswire/ -- The "United States Environmental PFAS Treatment Market, Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 3, 2020 /PRNewswire/ -- The "United States Environmental PFAS Treatment Market, Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.
  • This study investigates the United States Environmental PFAS Treatment Market that is segmented into 3 revenue categories: sample testing, site assessment, and treatment.
  • Leading stakeholders in the market, including testing laboratories, consulting engineers, and treatment solution providers have contributed to the research.
  • The market for sample testing, site assessment, and treatment has been growing very rapidly as a result of this ubiquitous contamination and increased public awareness.

All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study

Retrieved on: 
Tuesday, March 31, 2020
Pyrimidines, Organofluorides

The BALANCED study is an ongoing randomized, double-blind, placebo-controlled study in NASH patients.

Key Points: 
  • The BALANCED study is an ongoing randomized, double-blind, placebo-controlled study in NASH patients.
  • We are delaying the planned initiation of the BALANCED study cohort C in NASH patients who have compensated cirrhosis (F4), Child-Pugh Class A.
  • The Phase 2a BALANCED study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed adult patients with NASH.
  • AKR-001 is Akero's lead product candidate for NASH, currently being evaluated in the ongoing Phase 2a BALANCED study.

Inhance Technologies launches commercial process to eliminate PFAS from fluoropolymers

Retrieved on: 
Tuesday, March 24, 2020
Chemistry, Physical sciences, Chemical substances, Organofluorides, Fluoropolymers, Perfluorinated compounds, Thermoplastics, Perfluorooctanoic acid, Polytetrafluoroethylene, PFAS, Fluorine, Tetrafluoroethylene

Inhance Technologies said Fixpure, its process to eradicate PFAS from polytetrafluoroethylene (PTFE) and other fluoropolymers, has been developed in response to worldwide concerns regarding PFAS, and ahead of the planned implementation of the European Union's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations later this year.

Key Points: 
  • Inhance Technologies said Fixpure, its process to eradicate PFAS from polytetrafluoroethylene (PTFE) and other fluoropolymers, has been developed in response to worldwide concerns regarding PFAS, and ahead of the planned implementation of the European Union's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations later this year.
  • Inhance Technologies has spent the last two years developing a process to eliminate them without effecting product performance.
  • Inhance Technologies' process eliminates PFAS, including PFOA, down to non-detectable levels from resins, fine powders and waxes and is now available on a commercial scale at Inhance Technologies' Houston manufacturing site.
  • For more information on Inhance Technologies' PFAS-eliminating solution, visit www.pfoaelimination.com
    Founded in 1983, Inhance Technologies is a leader in the transformation of plastics and other polymeric substrates for higher performance through its portfolio of proprietary materials science technologies.

Inhance Technologies launches commercial process to eliminate PFAS from fluoropolymers

Retrieved on: 
Tuesday, March 24, 2020
Chemistry, Physical sciences, Chemical substances, Organofluorides, Fluoropolymers, Perfluorinated compounds, Thermoplastics, Perfluorooctanoic acid, Polytetrafluoroethylene, PFAS, Fluorine, Tetrafluoroethylene

Inhance Technologies said Fixpure, its process to eradicate PFAS from polytetrafluoroethylene (PTFE) and other fluoropolymers, has been developed in response to worldwide concerns regarding PFAS, and ahead of the planned implementation of the European Union's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations later this year.

Key Points: 
  • Inhance Technologies said Fixpure, its process to eradicate PFAS from polytetrafluoroethylene (PTFE) and other fluoropolymers, has been developed in response to worldwide concerns regarding PFAS, and ahead of the planned implementation of the European Union's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations later this year.
  • Inhance Technologies has spent the last two years developing a process to eliminate them without effecting product performance.
  • Inhance Technologies' process eliminates PFAS, including PFOA, down to non-detectable levels from resins, fine powders and waxes and is now available on a commercial scale at Inhance Technologies' Houston manufacturing site.
  • For more information on Inhance Technologies' PFAS-eliminating solution, visit www.pfoaelimination.com
    Founded in 1983, Inhance Technologies is a leader in the transformation of plastics and other polymeric substrates for higher performance through its portfolio of proprietary materials science technologies.

Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients

Retrieved on: 
Thursday, March 19, 2020
Chemistry, Organic compounds, Health, Ebola, Hepatotoxins, Favipiravir, Hydroxyarenes, Organofluorides, Pyrazines, Ritonavir, Pharmaceutical industry

The virus clearance rate is a well-established golden standard assessing the clinical effectiveness of an antiviral medication.

Key Points: 
  • The virus clearance rate is a well-established golden standard assessing the clinical effectiveness of an antiviral medication.
  • Significant clinical differences have been observed between the 35-patient experimental group treated with Favipiravir and the 45-patient control group treated with Lopinavir / Ritonavir.
  • Together these studies indicated the clinical efficacy and safety of Favipiravir, bringing hope to countries suffering from the epidemic.
  • As a famous Chinese pharmaceutical enterprise, Hisun has exported API (Active Pharmaceutical Ingredients) to occidental countries for a long period of time.

Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients

Retrieved on: 
Thursday, March 19, 2020
Chemistry, Organic compounds, Health, Ebola, Hepatotoxins, Favipiravir, Hydroxyarenes, Organofluorides, Pyrazines, Ritonavir, Pharmaceutical industry

The virus clearance rate is a well-established golden standard assessing the clinical effectiveness of an antiviral medication.

Key Points: 
  • The virus clearance rate is a well-established golden standard assessing the clinical effectiveness of an antiviral medication.
  • Significant clinical differences have been observed between the 35-patient experimental group treated with Favipiravir and the 45-patient control group treated with Lopinavir / Ritonavir.
  • Together these studies indicated the clinical efficacy and safety of Favipiravir, bringing hope to countries suffering from the epidemic.
  • As a famous Chinese pharmaceutical enterprise, Hisun has exported API (Active Pharmaceutical Ingredients) to occidental countries for a long period of time.

TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder to Treat Invasive Pulmonary Aspergillosis (IPA)

Retrieved on: 
Thursday, March 19, 2020
Biotechnology, Pharmaceutical, Health, Chemical compounds, Health, RTT, Organic compounds, Organofluorides, Pyrimidines, Tertiary alcohols, Astellas Pharma, Voriconazole, Itraconazole, Aspergillosis, Tacrolimus

Voriconazole is generally considered to be the most effective antifungal drug for treating Invasive Pulmonary Aspergillosis (IPA).

Key Points: 
  • Voriconazole is generally considered to be the most effective antifungal drug for treating Invasive Pulmonary Aspergillosis (IPA).
  • The Phase I clinical trial of Voriconazole Inhalation Powder is a randomized, double-blind, placebo-controlled study with inhalation route of administration to 64 healthy adult volunteers.
  • The main objectives of the Phase I clinical trial are to assess the safety, tolerability and pharmacokinetic profile of the Voriconazole Inhalation Powder in healthy subjects.
  • TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.

Addex Therapeutics Delays Start of Dipraglurant Pivotal Study and Reporting 2019 Full Year Audited Results

Retrieved on: 
Wednesday, March 18, 2020
Organic compounds, Neurological disorders, Chemical compounds, Dipraglurant, Imidazopyridines, Organofluorides, Parkinson's disease, Raseglurant

In addition, the company will delay reporting its full year 2019 audited financial results and associated investor conference call till April 8, 2020.

Key Points: 
  • In addition, the company will delay reporting its full year 2019 audited financial results and associated investor conference call till April 8, 2020.
  • Addex has taken the decision to postpone the start of the dipraglurant study due to the fact that the intended patient population is among the highest risk category for severe illness and death associated with COVID-19.
  • Addex will continue to work with its CRO and the study sites to continue preparations to start the study as soon as it is appropriate to do so.
  • Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is scheduled to enter a pivotal registration clinical trial for Parkinsons disease levodopa induced dyskinesia (PD-LID).

Fluoropolymer Films Market Slated to Surpass $3.11 Billion by 2026, Says Global Market Insights Inc.

Retrieved on: 
Monday, March 16, 2020
Chemistry, Physical sciences, Natural sciences, Thermoplastics, Organofluorides, Fluoropolymer, Polymers, Fluorine

The demand for fluoropolymer films in commercial building and new sports complexes is likely to contribute to the total market share over the forecast period.

Key Points: 
  • The demand for fluoropolymer films in commercial building and new sports complexes is likely to contribute to the total market share over the forecast period.
  • Based on end-use, the fluoropolymer films market is categorized into transportation, construction, medical & healthcare, industrial processing, electrical & electronics, and others.
  • The use of fluoropolymer films mainly in aerospace and automobile industry is anticipated to make a positive contribution to total segmental growth.
  • Fluoropolymer films are majorly used as protective films in the automobile industry and can withstand environmental wear and tear.